Medical Genetics of Acute Myeloid Leukemia PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Medical Genetics of Acute Myeloid Leukemia PDF full book. Access full book title Medical Genetics of Acute Myeloid Leukemia by Garden Grove Garden Grove Press. Download full books in PDF and EPUB format.
Author: Garden Grove Garden Grove Press
Publisher:
ISBN: 9781544837598
Category :
Languages : en
Pages : 288
Get Book Here
Book Description
This article collection reviews the medical genetics of acute myeloid leukemia and includes 30 papers by various authors. Topics include: Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia; Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis; Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia; Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia; Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia; A WIMSical approach to decoding DNA methylation in myeloid leukemia; A three-gene expression-based risk score can refine the European LeukemiaNet AML classification; A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints; Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling; Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations; Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia; The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML); Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations; Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia; Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia - association with young age and myeloid sarcomas?; Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays; Computational identification of the normal and perturbed genetic networks involved in myeloid differentiation and acute promyelocytic leukemia; Current findings for recurring mutations in acute myeloid leukemia; Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications; Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients; Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics; Long noncoding RNAs: pivotal regulators in acute myeloid leukemia; CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects; TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases; A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13); Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia; 5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia; Analysis of AML genes in dysregulated molecular networks; SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study; and A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia. Proceeds from the sale of this book go to the support of an elderly disabled person.
Author: Garden Grove Garden Grove Press
Publisher:
ISBN: 9781544837598
Category :
Languages : en
Pages : 288
Get Book Here
Book Description
This article collection reviews the medical genetics of acute myeloid leukemia and includes 30 papers by various authors. Topics include: Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia; Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis; Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia; Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia; Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia; A WIMSical approach to decoding DNA methylation in myeloid leukemia; A three-gene expression-based risk score can refine the European LeukemiaNet AML classification; A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints; Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling; Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations; Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia; The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML); Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations; Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia; Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia - association with young age and myeloid sarcomas?; Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays; Computational identification of the normal and perturbed genetic networks involved in myeloid differentiation and acute promyelocytic leukemia; Current findings for recurring mutations in acute myeloid leukemia; Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications; Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients; Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics; Long noncoding RNAs: pivotal regulators in acute myeloid leukemia; CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects; TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases; A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13); Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia; 5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia; Analysis of AML genes in dysregulated molecular networks; SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study; and A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia. Proceeds from the sale of this book go to the support of an elderly disabled person.
Author: Hillard M. Lazarus
Publisher: Springer Science & Business Media
ISBN: 1597454788
Category : Medical
Languages : en
Pages : 885
Get Book Here
Book Description
Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.
Author: Ingrid Jakobsen
Publisher: Linköping University Electronic Press
ISBN: 9176851958
Category :
Languages : en
Pages : 76
Get Book Here
Book Description
The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. Based on cytogenetic analysis, patients are divided into low risk, intermediate risk, and high-risk groups. While low risk patients have a high chance of reaching and remaining in remission after standard induction therapy, high-risk patients are likely to suffer from relapse and should be scheduled for allo-SCT when first complete remission is reached. The intermediate risk group consists of normal karyotype (NK) patients and those with karyotypes of uncertain clinical relevance, but the outcomes are heterogeneous. In NKAML patients, risk classification has improved with the addition of molecular markers including FLT3 internal tandem duplications (ITD) and mutations of NPM1 and CEBPA. Despite this development, there is a group of patients lacking reliable prognostic markers and in some cases the outcomes predicted do not match the outcomes observed, highlighting the need for additional markers. ABCB1 encodes a transporter protein responsible for the extrusion of cytotoxic compounds, including daunorubicin, over the cell membrane, and is a known resistance mechanism. Ara-C is subject to both activating and inactivating metabolic enzymes including DCK (activating), CDA and cN-II (inactivating). ABCB1, DCK, CDA and cN-II are all polymorphic, and SNPs affecting enzyme function and/or activity have potential as prognostic markers. In addition, recurrent IDH1/2 mutations lead to the expression of an enzyme with neomorphic activity associated with epigenetic alterations and disturbed differentiation. Mutations as well as a SNP in codon 105 of IDH1 have prognostic implications in AML, although the effects of different IDH mutations have been unclear. The aim of this thesis was to investigate SNPs in ABCB1 and genes associated with Ara-C metabolism, mutations in IDH1/2 and the IDH1 SNP, and their associations with treatment response and survival in AML. We show that the 1236C>T and 2677G>T SNPs in ABCB1 influence in vitro sensitivity towards AML drugs, with corresponding effects on NK-AML patient survival. These survival differences were seen mainly in patients lacking FLT3-ITD, further adding to the risk stratification. In contrast, the CDA SNPs 79A>C and -451C>T appear to influence survival mainly in FLT3-ITD positive cases. In conclusion, the above-mentioned SNPs have the potential to add important information to risk classifications especially in NK-AML patients with the ambiguous FLT3-ITD-/NPM1- or FLT3-ITD+/NPM1+ genotypes. In addition, we have shown that IDH2 R140 mutation is associated with impaired survival in AML, and that the IDH1 codon 105 SNP appears to confer a worse outcome in a subset of intermediate risk patients without FLT3-ITD. With the introduction of next generation sequencing into clinical diagnostics, IDH mutations may not only provide prognostic information but also guide the selection of patients for new drugs targeting the variant enzyme. Our results indicate that in addition to leukemia-specific mutations, constitutional SNPs may prove useful for further individualizing care-taking and should be considered when implementing these new techniques.
Author: Lalitha Nagarajan
Publisher: Springer Science & Business Media
ISBN: 0387692592
Category : Medical
Languages : en
Pages : 280
Get Book Here
Book Description
Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
Author: Rolf-Dieter Wegner
Publisher: Springer Science & Business Media
ISBN: 3642599184
Category : Medical
Languages : en
Pages : 464
Get Book Here
Book Description
Following a section on tissue culture, chromosome staining and basic information about karyotyping, this text presents nomenclature and quality standards, as well as protocols of relevance to comprehensive cytogenetic diagnostics.
Author: Robert J. Arceci
Publisher: Elsevier Inc. Chapters
ISBN: 0128061146
Category : Medical
Languages : en
Pages : 51
Get Book Here
Book Description
On first consideration, acute myeloid leukemia (AML) represents a nearly insurmountable challenge in terms of understanding it at the molecular level in large part because of its immense heterogeneity as well as its variability across different age groups. In addition, while significant progress has been made in the overall survival of subsets of patients with AML, many continue to show little progress in terms of positive treatment outcomes. Cytogenetic and initial molecular studies have resulted in the ability to stratify patients into specific risk categories that predict favorable-, intermediate- and poor-risk outcomes. However, these categories are limited in their ability to predict accurately how individual patients will respond to therapy and have not resulted in the ability to treat effectively patients with specific treatments. They have, however, resulted in excluding hematopoietic stem cell transplantation for patients with favorable-risk disease. Genome-wide analysis promises to improve both treatment and outcomes. The initial studies using whole-exon or whole-genome sequencing identified mutations in several novel genes that surprisingly were involved in regulating DNA methylation and chromatin structure. Subsequently, mutations were found in genes encoding transcription factors, signaling pathway modulators and genes involved in RNA splicing. Further analyses have identified mutations in key elements of miRNAs. Genome-wide methylation studies have highlighted key patterns that track with specific cytogenetic and gene mutations. Such epigenetic studies have led to the use of treatments directed to altering chromatin structure and DNA methylation. These treatments remain targeted specifically at specific enzymatic components of chromatin structure and function, but their key molecular consequences remain unclear and clinical responses unpredictable. RNA sequencing has led to the identification of both novel pathways of leukemia cell survival and unexpected fusion transcripts, which may ultimately be therapeutically targeted.
Author: Lalitha Nagarajan
Publisher: Springer
ISBN: 9780387565095
Category : Medical
Languages : en
Pages : 280
Get Book Here
Book Description
Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
Author: Mehrdad Payandeh
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages :
Get Book Here
Book Description
Genetics has an important role in the risk stratification and management of the patients with acute myeloid leukemia (AML). Molecular testing can't take the place of cytogenetic testing results, but has complementary role to help refine prognosis of the disease, especially within specific AML subgroups. Molecular genetic analysis of CEBPA, NPM1, and FLT3 is already the standard of care in AML patients, and mutations in several additional genes are assuming increasing importance. The French-American-British (FAB) classification and the World Health Organization (WHO) classification are the most classifications for AML. The aim of this chapter is a review on the role of genetic analysis in new treatments of AML.
Author: Robert C. Bast, Jr.
Publisher: John Wiley & Sons
ISBN: 111900084X
Category : Medical
Languages : en
Pages : 2004
Get Book Here
Book Description
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Author: Pier Paolo Pandolfi
Publisher: Springer Science & Business Media
ISBN: 3540345949
Category : Medical
Languages : en
Pages : 276
Get Book Here
Book Description
Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.
